Apollomics (NASDAQ:APLM) COO Acquires $300,000.00 in Stock

Apollomics Inc. (NASDAQ:APLM) COO Yi-Kuei Chen purchased 20,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $15.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the chief operating officer owned 121,248 shares in the company, valued at approximately $1,818,720. This trade represents a 19.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Apollomics Stock Down 0.9%

NASDAQ APLM opened at $23.70 on Thursday. The company has a 50-day moving average price of $18.63 and a 200-day moving average price of $17.38. Apollomics Inc. has a 52 week low of $3.66 and a 52 week high of $42.12.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent quarter. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.